Cooper Galvin, PhD, MS, BA

Cooper Galvin has worked in cardiometabolic disease prevention for over 15 years, spanning research, strategy, and diagnostics operations. He is CEO and co-founder of Endless Health, Inc. (EndlessDX), a vertically integrated preventive diagnostics company that combines a CLIA/CAP-certified LC-MS/MS laboratory, patented self-collection devices, and a 50-state physician network to bring advanced lipid and cardiometabolic testing directly to patients outside traditional clinical settings.

His work centers on closing the detection gap in cardiovascular risk, with an emphasis on underused biomarkers such as Lp(a) and ApoB. Under his leadership, EndlessDX partners with pharmaceutical sponsors to fund community screening programs in high cardiovascular incidence metros, pairing testing with physician review and care navigation so that identified patients reach treatment.

Cooper holds a PhD in Molecular Biophysics from Stanford University and previously served as a consultant at McKinsey & Company. He is also the founder of Future Advancers of Science and Technology 501c3, a nonprofit that pairs students from underserved communities with working scientists.